# NCT07131514 (NCT07131514)

> HRS-4642 in Combination With Gemcitabine and Albumin-bound Paclitaxel and Adebrelimab for Neoadjuvant and Adjuvant Treatment of Pancreatic Cancer

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT07131514
- Phase: PHASE2
- Status: RECRUITING
- Sponsor: Ruijin Hospital
- Conditions: Pancreatic Cancer
- Interventions: HRS-4642+AG +Adebrelimab
- Enrollment: 30
- Primary outcome: Adverse events (AEs)
- Primary outcome: Objective Response Rate (ORR)

## Preliminary discovery

Commentary in our index that names this trial so far. Final coverage is set when the report is built.

- X threads: 5

## Order

Focused, $750, price fixed at order: https://www.erudio.com/contact?report=nct07131514